Eris Lifesciences, a pharmaceutical company, announced a licensing agreement with Biocon to market insulin glargine in India. In 3FY23, Eris plans to introduce insulin glargine.
Gilead Sciences and MiroBio, a privately held biotechnology company with headquarters in the UK, declared that they had signed a legally binding agreement under which Gilead will buy MiroBio for about $405 million in cash, subject to usual adjustments.
With the hashtag #encurewithazure, Azure Pharmaceuticals started a high-quality generic range campaign to minimize the expense of the patient’s prescriptions. At AZURE, the company’s commitment to safeguarding the health and welfare of its customers serves as its focus.
Enhertu, developed by AstraZeneca and Daiichi Sankyo, has received a significant FDA approval, making it the first therapy specifically intended to treat metastatic or unresectable breast cancer that expresses low levels of HER2.
According to Innovent Biologics, the biopharmaceutical company would receive HK$2.42 billion ($307.88 million) from Paris based Sanofi to work together on the development of two cancer medications in China.
Amgen opted to acquire ChemoCentryx for $3.7 billion in order to obtain access to a potential game-changing anti-inflammatory medicine and surpass quarterly revenue projections for its therapy for bone disease.
Emgality, an FDA-approved migraine
preventive medication, had some of Eli
Lilly’s most disappointing Q2 sales
numbers, with revenues reaching $157.5
million, up just 1% from the same quarter
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website